Fate Therapeutics presented updated clinical data at ACR Convergence 2025 showing immune system remodeling and durable responses in patients with systemic lupus erythematosus (SLE) treated with its off-the-shelf FT819 CAR-T cell therapy. This suggests potential benefit in a difficult-to-treat autoimmune condition. $Fate Therap(FATE.US)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.